TY - JOUR
T1 - How 3 Academic Centers Prescribe Stereotactic Body Radiation Therapy for Primary Lung Cancer
AU - De Leo, Alexandra N.
AU - Dagan, Roi
AU - Amdur, Robert J.
AU - Yeung, Anamaria R.
AU - Li, Jonathan
AU - Brooks, Eric D.
AU - Gilbo, Philip
AU - Gomez, Daniel
AU - Chang, Joe Y.
AU - Ning, Matthew
N1 - Funding Information:
Sources of support: This work had no specific funding. Disclosures: Dr Amdur is the editor-in-chief of Practical Radiation Oncology; Dr Chang received research grants from Bristol-Myers Squibb and is a shareholder of Global Oncology One.
Publisher Copyright:
© 2022 American Society for Radiation Oncology
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Stereotactic body radiation therapy (SBRT) is commonly used to treat early-stage, node-negative primary lung cancer, but society guidelines provide limited information regarding several technical aspects of SBRT, leading to potential variation in practice. In this report, we present the technical details used by 3 academic institutions when treating a solitary primary lung tumor up to 5 cm in dimension with curative-intent SBRT. We provide specifications outlined in major active or recently completed clinical trials. Among the participating institutions, we discovered multiple divergences in treatment parameters, including, but not limited to, prescription dose and desired degree of heterogeneity within the target volume. It is unclear to what extent these differences in parameters might affect tumor control or toxicity, but updated consensus guidelines addressing the relevant SBRT prescription details may help standardize practice patterns.
AB - Stereotactic body radiation therapy (SBRT) is commonly used to treat early-stage, node-negative primary lung cancer, but society guidelines provide limited information regarding several technical aspects of SBRT, leading to potential variation in practice. In this report, we present the technical details used by 3 academic institutions when treating a solitary primary lung tumor up to 5 cm in dimension with curative-intent SBRT. We provide specifications outlined in major active or recently completed clinical trials. Among the participating institutions, we discovered multiple divergences in treatment parameters, including, but not limited to, prescription dose and desired degree of heterogeneity within the target volume. It is unclear to what extent these differences in parameters might affect tumor control or toxicity, but updated consensus guidelines addressing the relevant SBRT prescription details may help standardize practice patterns.
UR - http://www.scopus.com/inward/record.url?scp=85134786324&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134786324&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2022.02.006
DO - 10.1016/j.prro.2022.02.006
M3 - Article
C2 - 35219881
AN - SCOPUS:85134786324
SN - 1879-8500
VL - 12
SP - 496
EP - 503
JO - Practical radiation oncology
JF - Practical radiation oncology
IS - 6
ER -